GPR52 agonists attenuate ropinirole-induced preference for uncertain outcomes

Area of Science:

• Neuroscience
• Pharmacology
• Behavioral Science

Background:

• Dopamine D2/3 receptor agonists alleviate Parkinson's disease motor symptoms but can cause impulse control disorders, including gambling.
• G-protein-coupled receptor 52 (GPR52) is coexpressed with striatal D2 receptors and its activation can attenuate behaviors linked to dopamine signaling.
• Iatrogenic gambling disorder may involve striatal dopamine signaling, suggesting a potential therapeutic target.

Purpose of the Study:

• To investigate if GPR52 agonists can block drug-induced increases in preference for uncertain outcomes.
• To determine if GPR52 agonists mitigate gambling disorder-like behaviors without impacting baseline decision-making.

Main Methods:

• Utilized the rat betting task (rBT) where rats choose between a guaranteed reward and a gamble.
• Administered GPR52 agonists (BD442618, BD502657) alone and in combination with d-amphetamine or chronic ropinirole.
• Assessed changes in preference for uncertainty and baseline choice patterns.

Main Results:

• GPR52 agonists BD442618 and BD502657 did not alter baseline decision-making in the rBT.
• Both agonists successfully attenuated the increased preference for uncertainty induced by acute d-amphetamine and chronic ropinirole.
• These findings suggest GPR52 agonists can block hyperdopaminergic state-induced risk-taking behavior.

Conclusions:

• GPR52 agonists represent a novel therapeutic strategy for iatrogenic gambling disorder.
• These compounds may be beneficial in managing hyperdopaminergic states associated with Parkinson's disease treatments.
• Further research into GPR52 agonists could lead to safer and more effective Parkinson's therapies.